Nicotinamide Mononucleotide (NMN)
NAD+ precursor; early human trials suggest metabolic & energy benefits, especially in older adults.
Evidence last reviewed: 04 Apr 2026
- •those with a history of cancer
- •pregnant or breastfeeding individuals
- •people on certain medications
Current evidence shows NMN reliably raises NAD+ levels and may improve insulin sensitivity and muscle endurance in older adults. However, the long-term effects and safety in humans remain unclear, and more research is needed.
NAD+ levels / metabolic markersOlder adults; insulin-resistant individuals · RCTs (phase I/II)Moderate
Reliably raises blood NAD+; some improvements in insulin sensitivity & muscle endurance in older adults.
Forms & usage▾
Take 250-500 mg daily, preferably in the morning.
Safety & trade-offs2▾
May fuel pre-existing cancer cell growth in preclinical models (NAD+ supports cell proliferation) — human significance unclear
FDA has raised exclusion concerns for NMN as a dietary supplement — regulatory status is legally ambiguous in the US
●High ●Moderate ● Low / note